Cambridge Clinical Laboratories
Cambridge Clinical Laboratories is a UKAS-accredited Cambridge-based specialty diagnostics laboratory providing oncology, hereditary cancer, companion diagnostics, and virology testing services to UK healthcare professionals and partner private clinics, now operating as part of Source BioScience.
- Company typePrivate
- Founded2005
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cambridge Clinical Laboratories does
Cambridge Clinical Laboratories (CCL) is a UK-based personalised healthcare testing laboratory headquartered in Cambridge, with UKAS accreditation for medical testing services. The company specialises in oncology diagnostics, virology, hereditary cancer testing, companion diagnostics, and pharmacogenetic testing, employing molecular diagnostics and next-generation sequencing as its underlying technology platforms. Its product portfolio spans screening, aggressiveness assessment, treatment-guidance, and surveillance tests across multiple tumour types, including prostate, breast, lung, bladder, bowel, stomach, and thyroid cancers, alongside a 31-gene hereditary cancer panel and tests for biomarkers such as HER2, BRCA, PIK3CA, PD-L1, EGFR, KRAS, and BRAF.
CCL's product strategy is built on curating and distributing a portfolio of clinically validated, third-party developed proprietary tests — notably Bladder EpiCheck (Nucleix), EarlyCDT Lung, Stockholm3 (Karolinska Institutet), Proclarix (Proteomedix), and Prostatype (Prostatype Genomics) — rather than developing tests in-house. The business operates on a B2B2C model: revenue is generated through per-test fees (e.g., FIT at £40 per test directly) billed primarily to healthcare professionals (GPs, consultant surgeons, urologists) and partner private clinics (Goodbody Clinic, Innermost Healthcare, Remedi Health), with NHS engagement via trials such as the Bladder EpiCheck study at Western General Hospital Edinburgh. Most tests are not sold directly to patients; instead, patients access them through healthcare provider referrals or partner clinic platforms.
In April 2025, CCL was acquired by Source BioScience UK Ltd, a provider of genomic services and histopathology diagnostics, integrating CCL's molecular diagnostics capability into a broader laboratory services platform spanning R&D through clinical trial support. Following the acquisition, CCL continues to operate as a specialty cancer testing provider within Source BioScience's portfolio.
Cambridge Clinical Laboratories firmographics
Firmographics- Name
- Cambridge Clinical Laboratories
- Legal name
- Cambridge Clinical Laboratories Ltd
- Website
- https://camclinlabs.co.uk
- Company type
- Private
- Founded year
- 2005
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Cambridge Clinical Laboratories is a UKAS-accredited Cambridge-based specialty diagnostics laboratory providing oncology, hereditary cancer, companion diagnostics, and virology testing services to UK healthcare professionals and partner private clinics, now operating as part of Source BioScience.
- Ownership category
- akta.pro rank
Cambridge Clinical Laboratories industry classification
Industry- Product category
- Clinical Diagnostic Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Reference & Esoteric Testing Laboratories (HLAFAMAJ)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Central Laboratory Services (Core Lab Operations) (HLAGAEAA)
Keywords
Where Cambridge Clinical Laboratories is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Cambridge Clinical Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Laboratory Diagnostic Testing Services: CCL provides UKAS accredited personalised healthcare testing services including oncology, virology, pharmacogenetic, and hereditary cancer testing to healthcare professionals and organizations. Revenue generated through test fees charged for diagnostic services.
- Clinical Testing: Following acquisition by Source BioScience in April 2025, CCL now operates as part of Source BioScience's complete laboratory service portfolio, supporting clinical trials and diagnostics from R&D through preclinical and clinical stages.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | FIT Testing - Bowel Cancer Screening |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels4 records
Cambridge Clinical Laboratories product offering
Product offeringCore offering
Cambridge Clinical Laboratories is a UKAS accredited clinical diagnostic laboratory that provides personalised healthcare testing services to healthcare professionals and organisations. Its core offering is a portfolio of oncology, hereditary cancer, companion diagnostic, and virology tests, including proprietary and partner-developed assays such as Bladder EpiCheck, EarlyCDT Lung, Stockholm3, Proclarix, Prostatype, FIT testing, and a 31-gene hereditary cancer panel. Tests are ordered by GPs, consultants, and specialist urologists and delivered through partner clinics and NHS engagements.
Product overview
Cambridge Clinical Laboratories (CCL) is a UK-based personalised healthcare testing laboratory offering UKAS accredited testing services. The company operates as a platform of specialized cancer and diagnostic testing services rather than a single unified product. The portfolio includes: oncology testing services (prostate, breast, lung, bladder, bowel, stomach, thyroid cancers); hereditary cancer genetic testing panels; companion diagnostics for treatment guidance; and specialized tests including EarlyCDT Lung, Stockholm3, Proclarix, Prostatype, Bladder EpiCheck, and FIT testing. The company was acquired by Source BioScience in April 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology Testing Services
- Bladder EpiCheck
Quantifiable outcome
- 99.3% NPV for bladder cancer detection
- +3 more outcomes
Companies that use Cambridge Clinical Laboratories
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles3 records
Cambridge Clinical Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Cambridge Clinical Laboratories partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Source BioScience UK LtdcoreIn April 2025, Source BioScience acquired Cambridge Clinical Laboratories. The acquisition complements Source BioScience's established capabilities in genomics and multi-omics, expanding its clinical offering to provide a complete laboratory service portfolio from R&D through clinical stages.
- NucleixcoreNucleix developed Bladder EpiCheck, a urine test for bladder cancer detection. CCL offers this test in the UK as part of their bladder cancer portfolio, with ongoing NHS trial collaboration.
- Prostatype GenomicscoreProstatype Genomics developed Prostatype, a genetic test for determining prostate cancer aggressiveness. CCL is an authorized provider of this test in the UK.
- ProteomedixcoreProteomedix developed Proclarix, a protein-based blood test for prostate cancer risk assessment in the PSA grey zone. CCL offers this test in the UK.
- Karolinska InstitutetcoreKarolinska Institutet developed Stockholm3, an advanced screening test for aggressive prostate cancer. Validated on over 75,000 men, the test is included in European and American prostate cancer guidelines.
- Western General Hospital EdinburghcoreCCL collaborating with Nucleix and Dr Mariappan at Western General Hospital Edinburgh on NHS trial for Bladder EpiCheck, commencing Summer 2023 to evaluate replacing up to half of surveillance cystoscopies.
- Radboud University Medical CentreminorFirst hospital to make Bladder EpiCheck standard-of-care for bladder cancer patients. Professor Witjes reduces cystoscopies by alternating with Bladder EpiCheck.
- Goodbody CliniccoreGoodbody Clinic is a partner healthcare provider offering CCL tests including FIT, EarlyCDT Lung, Stockholm3, and Proclarix through their online platform and clinic locations.
- Innermost HealthcarecoreInnermost Healthcare offers multiple CCL tests (EarlyCDT, Bladder EpiCheck) at their Cardiff clinic and provides home visit phlebotomy services UK-wide.
- Prostate MattersminorProstate Matters is a not-for-profit organization that has endorsed Stockholm3 and provides information about the test on their website.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Cambridge Clinical Laboratories competitors and assessment
Company assessmentDirect peers
- Oncologica UK: Cambridge-based molecular oncology diagnostics lab offering NGS-based cancer profiling and companion diagnostics, directly comparable to CCL in geography, market, and specialized cancer testing focus.
- The Doctors Laboratory (TDL): Large UK private pathology/reference laboratory serving clinicians and private healthcare providers, overlapping strongly with CCL's B2B lab-testing model for the private and NHS sectors.
- Randox Laboratories: UK diagnostics company offering clinical and cancer-related testing to healthcare providers, comparable to CCL in market, testing menu, and B2B distribution.
Broad incumbents
- SYNLAB UK & Ireland: Major clinical laboratory network providing diagnostic testing to NHS and private providers across the UK, overlapping with CCL's core lab services at far larger scale.
- Exact Sciences: Global cancer screening and diagnostics company (Cologuard, Oncotype); competes in the cancer early-detection and prognostic testing category CCL operates in.
- Eurofins Scientific: Global testing and clinical diagnostics group offering broad laboratory services, a much larger incumbent overlapping CCL's clinical lab and companion diagnostics activities.
Others
- Source BioScience: CCL's parent company providing genomics, histopathology and clinical trial support; adjacent and now the owner rather than a direct market competitor.
Emerging players
- Nonacus: UK genomics company developing liquid biopsy and cancer detection assays including bladder cancer, overlapping with CCL's oncology molecular testing niche.
- GRAIL: Multi-cancer early detection company whose blood-based screening mission overlaps with CCL's early-detection oncology test portfolio.
Regional players
- Medichecks: UK consumer-facing diagnostic testing provider using accredited labs; overlaps with CCL's UK health-testing market though via a more direct-to-consumer model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Cambridge Clinical Laboratories social profiles
Digital presenceCambridge Clinical Laboratories compliance and trust
Trust signalCompliance1 record
Cambridge Clinical Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cambridge Clinical Laboratories leadership team
Management profileNumber of profiles
Cambridge Clinical Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cambridge Clinical Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cambridge Clinical Laboratories
What does Cambridge Clinical Laboratories do?
Cambridge Clinical Laboratories is a UKAS accredited clinical diagnostic laboratory that provides personalised healthcare testing services to healthcare professionals and organisations. Its core offering is a portfolio of oncology, hereditary cancer, companion diagnostic, and virology tests, including proprietary and partner-developed assays such as Bladder EpiCheck, EarlyCDT Lung, Stockholm3, Proclarix, Prostatype, FIT testing, and a 31-gene hereditary cancer panel. Tests are ordered by GPs, consultants, and specialist urologists and delivered through partner clinics and NHS engagements.
Is Cambridge Clinical Laboratories a public or private company?
Cambridge Clinical Laboratories is a private company. It is classified as corporate owned and is currently acquired.
When was Cambridge Clinical Laboratories founded?
Cambridge Clinical Laboratories was founded in 2005. It employs 11 to 50 people.
Where is Cambridge Clinical Laboratories based?
Cambridge Clinical Laboratories is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Cambridge Clinical Laboratories make money?
Two revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are clinical Testing.
Who are Cambridge Clinical Laboratories's main competitors?
Direct peers on record are Oncologica UK, The Doctors Laboratory (TDL) and Randox Laboratories. Broad incumbents are SYNLAB UK & Ireland, Exact Sciences and Eurofins Scientific. Source BioScience is listed as an others. Emerging players are Nonacus and GRAIL. Medichecks is listed as a regional player.
Does Cambridge Clinical Laboratories have an API?
No public API is recorded for Cambridge Clinical Laboratories.
What industry is Cambridge Clinical Laboratories in?
Cambridge Clinical Laboratories's product category is Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAMAJ, Reference & Esoteric Testing Laboratories, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.